Video

Pharmacist Medication Insights: Somapacitan (Sogroya) for Growth Hormone Deficiency

Somapacitan (Sogroya; Novo Nordisk) injection is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

Somapacitan (Sogroya; Novo Nordisk) injection is approved for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

The human growth hormone analogue is administered via subcutaneous injection once weekly.

Somapacitan acts similarly to human growth hormone. After injection, the drug attaches to a protein in the blood called albumin, which allows it remain in the body for longer. This enables weekly administration of Sogroya, which is favorable to the daily dosing of other growth hormone replacement therapies.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Lenacapavir | Image Credit: luchschenF | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.